Tag Archives: OncoGenex

October, 2016

13 October
OncoGenex’s Custirsen Fails to Meet Primary Endpoint in Late-Stage NSCLC Trial

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 13, 2016 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of the Phase 3 ENSPIRIT trial of custirsen in patients whose non-small cell lung cancer (NSCLC) has progressed following initial treatments. The trial did not meet the primary …
Share

17 August
OncoGenex’s Prostate Cancer Candidate Fails in Late-Stage Trial

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 16, 2016 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel. The trial did …
Share

22 January
OncoGenex’s NSCLC Candidate Fails to Meet PFS Goal in Mid-Stage Trial

BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 20, 2016 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required …
Share